Incorporating D2D to Current Cellular Communication System

A device-to-device (D2D) group works as relay nodes to aid the information delivery from a source to a destination in cellular communication network. Within this system, we propose a communication mechanism to aid traditional cellular communication and correspondingly borrow some channel resource from traditional cellular communication system for D2D communication. On one side, to aid cellular communication, we propose a modified Alamouti scheme which does not modify the operation at the base station. This makes our proposed scheme consistent with previous cellular communication system. On the other side, there are many competitive D2D groups that want to potentially utilize the borrowed channel resource from traditional cellular system for delivering their own information. We model this competition as a game and utilize game theory technique to solve this competition problem

Incorporating D2D to Current Cellular Communication System

A device-to-device (D2D) group works as relay nodes to aid the information delivery from a source to a destination in cellular communication network. Within this system, we propose a communication mechanism to aid traditional cellular communication and correspondingly borrow some channel resource from traditional cellular communication system for D2D communication. On one side, to aid cellular communication, we propose a modified Alamouti scheme which does not modify the operation at the base station. This makes our proposed scheme consistent with previous cellular communication system. On the other side, there are many competitive D2D groups that want to potentially utilize the borrowed channel resource from traditional cellular system for delivering their own information. We model this competition as a game and utilize game theory technique to solve this competition problem

αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib

Case presentation Here we report a case of refractory EOC in a patient who had relapsed after multiline chemotherapy. The patient received autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (αPD-1). The modified T cells were called αPD-1-mesoCAR-T cells. After infusion, the copy number and PD-1 antibody secretion of the CAR-T cells were increased in the blood. By application of multimodality tumor tracking, MRI of the liver showed shrinkage of metastatic nodules from average diameter of 71.3–39.1 mm at month 2. The patient achieved partial response and survived more than 17 months. IL-6 levels in the patient fluctuated from the baseline to 2–4-folds after treatment, but side effects were mild with only grade 1 hypertension and fatigue.Conclusion αPD-1-mesoCAR-T cell therapy combined with apatinib demonstrates a potential therapeutic effect on advanced refractory ovarian cancer.Trial registration number NCT03615313